Compositions and methods for treating hepatitis C virus

摘要

Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.

主权项

1. A pharmaceutical composition comprising:
a) about 25% to about 35% w/w of crystalline GS-7977 having the structureand
b) at least one pharmaceutically acceptable excipient, wherein the crystalline GS-7977 has XRPD 2θ-reflections (°) at about: 6.1 and 12.7.